A Breakthrough In Omega-3 Absorption
The world’s first clinically proven technology to optimize absorption of EPA and DHA.
A New Breakthrough From The Omega-3 Pioneers
As the pioneer and market leader for high concentrate omega-3 in both food and pharma, BASF's omega-3 expert team is constantly seeking ways to improve the benefits of omega-3 fatty acids as an essential health solution.
BASF's new absorption accelerating technology significantly enhances the absorption of omega-3 in the body, increasing bioavailability by a minimum of 4X compared to leading high-concentrate omega-3 oils.
Clinically proven and consumer tested benefits
Min. 4X higher absorption* of EPA & DHA combined
Higher guarantee of uptake of the omega-3 consumed
Higher flexibility in day to day usage; not dependent on intake with large and/or fat-based meals
Reduced experience of reflux and fish burps in consumer testing
The current challenge
Despite increasing concentration of omega-3 supplements in recent years, consumption does not automatically mean we get the full benefit. In fact, several factors influencing uptake of omega-3 in the body.
Ideally, omega-3 supplements are taken together with a fatty meal. This combination specifically triggers the release of enzymes and emulsifiers which help solubilize and digest fats. However, many people take their supplements without food or fat-based meals.
How it works
To solve for sub-optimal omega-3 absorption, BASF Omega-3 Verbund scientists have developed an absorption accelerating formulation of highly concentrated omega-3 which, in contact with water, forms millions of tiny droplets in a micro-emulsion.
This system ensures the optimal absorption of the valuable omega-3 fatty acids independently from large and/or fat-based meals.
EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are long-chain omega-3 polyunsaturated fatty acids (omega-3s) that are abundant in fish, shellfish, and some algae and genetically engineered plants. (source: GOED; http://www.goedomega3.com/about-epa-and-dha)
The body needs omega-3s to develop and function optimally in every stage of life. There are more than 30,000 published studies on EPA and DHA, including more than 3,700 human clinical trials. The vast body of science associated with omega-3s supports consumption for overall wellness, including heart, brain and eye health. (source: GOED; http://www.goedomega3.com/about-epa-and-dha)
GOED recommends consuming 500mg of EPA and DHA per day for general health, and higher quantities for specific life stages or health conditions. Most of the global population consumes significantly less EPA and DHA than recommended. Consumers can learn more about EPA and DHA at AlwaysOmega3s.com (source: GOED; http://www.goedomega3.com/about-epa-and-dha)
The emulsifiers used in the absorption accelerating technology are fatty acids and polysorbates. The highly concentrated omega-3s are mixed with emulsifiers to form a miscible, clear solution (a pre-emulsion).
The polysorbates follow the food as it passes through the gastrointestinal system. They are not absorbed from the gastrointestinal tract. The time it takes for food to transit the digestive system varies between individuals and by the type and amount of food consumed. The total transit time from ingestion to egestion can therefore take from 6 hours to 2 days.
The absorption accelerating technology does not directly interact with the gastrointestinal system. The absorption accelerating technology ensures all omega-3 microdroplets are covered with emulsifiers. These are subsequently solubilized in the stomach and then more effectively absorbed.
It doesn’t change the amount you are taking though it will improve the amount of benefit you experience. A full portion of food with a high fat content is required to ensure optimum absorption of omega-3 into the body. If an omega-3 supplement is taken on an empty stomach or with only a small amount of food the release of bile salts are not fully triggered, which results in larger drops of fat that cannot be digested effectively or that are only partly absorbed. In this case the remaining omega-3 are then transported down the gastrointestinal tract and egested together with faeces.
The absorption accelerating technology makes the bile salts redundant in solubilizing the fats of the omega-3 supplement and guarantees its effective absorption.
Yes. In clinical studies of omega-3 supplements with absorption accelerating technology, EPA & DHA combined has been proven to be absorbed more than 4 times compared to the same omega-3 supplement without the absorption accelerating technology. The clinical studies were performed with omega-3 supplements taken in the morning without food.
In summary the US patent covers a food supplement or nutritional supplement composition comprising: a range of fish oil concentrates from 25% to 75% EPA + DHA in combination with one or more surfactants and at least one free fatty acid.
Click here for the full US patent: https://www.google.ch/patents/US9532963
Yes, the absorption accelerating technology works independently of what time the capsules are taken.
Yes, it will still provide increased absorption of EPA & DHA combined compared with the same omega-3 supplement without absorption accelerating technology. The additional effect is relatively smaller since the body’s own digestion-absorption system is also activated. In a clinical study, the absorption accelerating technology improved the absorption of omega-3 by 35% when given together with a fat-containing meal.
The absorption accelerating technology ensures that micro-droplets of omega-3 are formed to create an emulsion which enables the body to digest and absorb the omega-3 more effectively. This may reduce the effects of reflux or fish-burps.
In consumer tests, those with previous history of reflux and fish-burps reported reduced incidences following a week-long trial period.
To date the BASF Omega-3 Verbund absorption accelerating technology is unique in claiming improved absorption of EPA & DHA combined at a minimum of 4X compared to leading pharmaceutical grade omega-3 oils.
All clinical studies on the absorption accelerating technology to date have been investigated on a single dose, in regular gelatin capsule (soft-gel capsules) format, taken in the morning without food. In ongoing studies, the absorption accelerating technology is taken daily over a longer period of time to determine the long-term effect of the effective absorption and implications on how the dose may be adjusted.
The omega-3 index is a globally recognized measure of how much omega-3 our red blood cells contain. The index is known to reflect how much omega-3 is incorporated into other cells of the body, which is partly dependent on omega-3 concentration in the blood while cells form, develop and grow. We have therefore good reason to believe that improved absorption leads to a higher and more rapidly improved omega-3 index.
The omega-3 oils used in the absorption accelerating technology are products of highest possible quality. They meet the strictest specifications available and are produced in a factory audited and approved by the FDA for production of pharma grade omega-3 concentrates. The production follows HACCP principles and it is certified under FSSC 22000 for compliance to food safety.
BASF Omega-3 Verbund oil quality supersedes all globally recognized standards for fish oil and omega-3.
Please feel free to contact us for all enquiries related to our new Absorption Accelerating Technology or other products in our portfolio: email@example.com.
*These claims have not been evaluated by the Food and Drug Administration. This technology is not intended to diagnose, treat, cure, or prevent any disease.